Calamos Advisors LLC Has $253,000 Stock Holdings in Iradimed Corporation (NASDAQ:IRMD)

Calamos Advisors LLC lessened its stake in shares of Iradimed Corporation (NASDAQ:IRMD) by 8.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,596 shares of the medical equipment provider’s stock after selling 435 shares during the period. Calamos Advisors LLC’s holdings in Iradimed were worth $253,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IRMD. R Squared Ltd acquired a new stake in shares of Iradimed in the fourth quarter worth $30,000. Huntington National Bank grew its stake in shares of Iradimed by 51.3% in the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock worth $75,000 after acquiring an additional 504 shares during the last quarter. Gladius Capital Management LP grew its stake in shares of Iradimed by 126.6% in the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 965 shares during the last quarter. Quantbot Technologies LP grew its stake in shares of Iradimed by 83.0% in the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after acquiring an additional 1,052 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Iradimed in the third quarter worth $126,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Iradimed from a “strong-buy” rating to a “buy” rating in a research note on Wednesday.

Insider Buying and Selling

In related news, CFO John Glenn sold 2,500 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the transaction, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at $237,470.94. This trade represents a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 37.10% of the stock is owned by company insiders.

Iradimed Price Performance

Shares of IRMD stock opened at $62.67 on Thursday. The stock has a market cap of $794.03 million, a P/E ratio of 42.92 and a beta of 0.82. Iradimed Corporation has a one year low of $40.18 and a one year high of $63.29. The stock has a fifty day moving average price of $56.49 and a 200 day moving average price of $51.55.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.